About 600 results
Open links in new tab
  1. Endo - Home | Introducing Keenova and Par Health

    Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products. Stay tuned for updates.

  2. Careers | Endo

    Beware of fraudulent recruiters falsely claiming to represent Endo. We never send payments for equipment or request personal financial information during recruitment.

  3. Products | Endo

    Discover Endo's comprehensive range of high-quality healthcare products, meticulously designed to meet the needs of patients across the U.S. This product information is intended for U.S. …

  4. Contact & Locations | Endo

    Contact & Locations Endo Global Headquarters Malvern 9 Great Valley Parkway Malvern, PA 19355 Phone: +1-484-216-0000

  5. Mallinckrodt, Endo Announce Planned Leadership Team for …

    Jun 9, 2025 · Mallinckrodt and Endo commenced mailing of the definitive joint proxy statement/prospectus to shareholders of Mallinckrodt and Endo, respectively, on or about May …

  6. Mallinckrodt and Endo to Combine to Create a Global, Scaled ...

    Mar 13, 2025 · Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after the close of the transaction and intend to …

  7. Focus Areas | Endo

    Endo is boldly innovating in pursuit of transforming health and health system burdens. Through our long-standing work in endocrinology, orthopedics, and urology, as well as in hospital …

  8. Our Purpose | Endo

    Meet Our Team Our team members are unmatched in their ability to solve problems and make a difference for the people we serve. Discover more about Endo’s culture, our meaningful work, …

  9. Investors | Endo - Overview

    Oct 9, 2025 · Mallinckrodt and Endo have merged to create a global, scaled, diversified therapeutics leader. Visit our new Investor Relations website at ir.mallinckrodt.com for up-to …

  10. Mallinckrodt and Endo Announce Significant Progress in Proposed …

    As announced on March 13, 2025, the proposed Mallinckrodt and Endo transaction envisions the spin-off of the combined generic pharmaceuticals businesses and Endo's sterile injectables …